pp-260 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Neurological disease
Clinical stage: Phase 2
Modality: Small molecule
Mechanism & Target: CNS modulator, Pain modulator
Route & form: Oral
Differentiation: First-in-class, Non-opioid NCE, Morphine or Gabapentin-comparable analgesic effect on acute & neuropathic pain as well as inflammatory pain.
Manufacturer #39674
A clinical-stage biopharmaceutical company focused on neurology. Developing a small molecule therapeutic targeting neurology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None